This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Developments in science and technology have played a significant role in Pakistan's infrastructure, linking the nation to the global community. Each year, the Pakistan Academy of Sciences and the government invite scientists worldwide to the International Nathiagali Summer College on Physics. In 2005, Pakistan hosted an international seminar on "Physics in Developing Countries" for the International Year of Physics. Pakistani theoretical physicist Abdus Salam won a Nobel Prize in Physics for his work on the electroweak interaction. Pakistani scientists have made notable contributions in mathematics, biology, economics, computer science, and genetics. In chemistry, Salimuzzaman Siddiqui identified the medicinal properties of the neem tree's components. Ayub K. Ommaya developed the Ommaya reservoir for treating brain conditions. Scientific research is integral to Pakistani universities, national laboratories, science parks, and the industry. Abdul Qadeer Khan spearheaded Pakistan's HEU-based gas-centrifuge uranium enrichment program for its atomic bomb project. He established the Kahuta Research Laboratories (KRL) in 1976, serving as both its senior scientist and the Director-General until his retirement in 2001. Besides atomic bomb project, he made significant contributions in molecular morphology, physical martensite, and their applications in condensed and material physics. In 2023, Pakistan ranked 26th globally in published scientific papers. The influential Pakistan Academy of Sciences guides the government on science policies.
Gastric pentadecapeptide BPC-157 (also known as Body Protection Compound 157, bepecin, or PL 14736) is a synthetic fifteen amino acid oligopeptide derived from a protein found in human gastric juice. BPC-157 has been studied primarily in laboratory animals. BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans. The peptide has gained popularity among athletes and the general public for injury recovery, leading the World Anti-Doping Agency to ban it in 2022. Health authorities discourage its use due to insufficient human safety data, and some jurisdictions have restricted it as a prescription-only medicine despite it not being available through legitimate prescriptions. Additionally, because the compound promotes blood vessel formation (angiogenesis), there are theoretical concerns about potential cancer promotion that require further investigation. The peptide was discovered during research on human gastric juice. The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. BPC-157 is stable at room temperature and bioavailable in rodent models when administered IM or IV. The peptide demonstrates unusual stability in human gastric juice, remaining intact for more than 24 hours.
It also occurs in humans as a metabolite from the thyrotropin-releasing hormone (TRH) and exhibits a wide variety of central nervous system, endocrine, electrophysiological, and cardiovascular effects. Molecules based on a cyclo(L-His-L-Pro) core have been studied extensively as possible nootropic drugs.
Oxymorphone, sold under the brand names Numorphan and Opana among others, is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes; after oral administration it begins after about 30 minutes and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high abuse potential. Oxymorphone was developed in Germany in 1914. It was patented in 1955 and approved for medical use in 1959. In June 2017 the FDA asked Endo Pharmaceuticals to remove its product from the US market. This was in part due to the opioid epidemic in the US, and the fact that a 2012 reformulation failed to stop illicit injection of the drug. Endo responded by voluntarily removing Opana ER from the market a month later. Generic versions of extended-release oxymorphone, such as those manufactured by Amneal Pharmaceuticals, are still available in the US.
=== Ovarian cancer and other === In 2008, the submission was announced of a registration dossier to the European Medicines Agency and the FDA for Yondelis when administered in combination with pegylated liposomal doxorubicin (Doxil, Caelyx) for the treatment of women with relapsed ovarian cancer. In 2011, Johnson & Johnson voluntarily withdrew the submission in the United States following a request by the FDA for an additional phase III study to be done in support of the submission. Trabectedin is also in phase II trials for prostate, breast, and paediatric cancers.
Sources: en.wikipedia.org
=== Conversion of pyruvate into oxaloacetate for the citric acid cycle === Pyruvate molecules produced by glycolysis are actively transported across the inner mitochondrial membrane, and into the matrix where they can either be oxidized and combined with coenzyme A to form CO2, acetyl-CoA, and NADH, or they can be carboxylated (by pyruvate carboxylase) to form oxaloacetate. This latter reaction "fills up" the amount of oxaloacetate in the citric acid cycle, and is therefore an anaplerotic reaction (from the Greek meaning to "fill up"), increasing the cycle's capacity to metabolize acetyl-CoA when the tissue's energy needs (e.g. in heart and skeletal muscle) are suddenly increased by activity. In the citric acid cycle all the intermediates (e.g. citrate, iso-citrate, alpha-ketoglutarate, succinate, fumarate, malate and oxaloacetate) are regenerated during each turn of the cycle. Adding more of any of these intermediates to the mitochondrion therefore means that that additional amount is retained within the cycle, increasing all the other intermediates as one is converted into the other. Hence the addition of oxaloacetate greatly increases the amounts of all the citric acid intermediates, thereby increasing the cycle's capacity to metabolize acetyl CoA, converting its acetate component into CO2 and water, with the release of enough energy to form 11 ATP and 1 GTP molecule for each additional molecule of acetyl CoA that combines with oxaloacetate in the cycle.
The design process at Ilyushin was managed by Sergey Ilyushin's successor as head of the bureau, Genrikh Novozhilov. The timescale announced in 1973 envisaged first flight in 1976 and service entry in time for the Moscow Olympics in 1980. The prototype flew at Khodynka airfield (where Ilyushin's experimental factory was) on December 22, 1976 (Soviet airliners often flew before the close of calendar years to meet the requirements of five-year plans). It was announced that the type had a patented electromagnetic pulse deicing system. which used 500 times less energy than conventional deicers. It is claimed that over 50 new technological processes were introduced into Soviet practice as a result of the Il-86 programme. The initial test programme was flown by Ilyushin staff, ending two months ahead of schedule on October 20, 1978. Other sources claim that these tests were completed on 22 September 1978. (According to a faster schedule announced at the time of the first flight, Ilyushin tests were to have ended in time for the 60th anniversary of the October Revolution on November 7, 1977.) In-house testing involved speeds up to Mach 0.93 and bank angles up to 11 degrees greater than specified. Initial certification flying by pilots independent of Ilyushin ended on June 6, 1977. State acceptance trials began on April 24, 1979, and ended on December 24, 1980. Certification by Gosaviaregistr SSSR [the USSR State Aviation Registry] was granted under certificate number 10–86. The Il-86 entered Aeroflot service on 26 December the same year.
== Clinical Significance == Abnormally high levels of gastrin, known as Hypergastrinemia, can result from conditions such as Atrophic gastritis and Pernicious anemia. Gastrin-17 has also been studied in relation to gastric cancer, as elevated levels may contribute to tumor growth in the stomach lining.
=== Chemistry === The aforementioned chemical shift came as a disappointment to physicists who had hoped that the resonance frequency of each nuclear species would be constant in a given magnetic field. But about 1951, chemist S. S. Dharmatti pioneered a way to determine the structure of many compounds by studying the peaks of nuclear magnetic resonance spectra. It can be a very selective technique, distinguishing among many atoms within a molecule or collection of molecules of very similar type but which differ only in terms of their local chemical environment. NMR spectroscopy is used to unambiguously identify known and novel compounds, and as such, is usually required by scientific journals for identity confirmation of synthesized new compounds. See the articles on carbon-13 NMR and proton NMR for detailed discussions. A chemist can determine the identity of a compound by comparing the observed nuclear precession frequencies to known or predicted frequencies. Further structural data can be elucidated by observing spin–spin coupling, a process by which the precession frequency of a nucleus can be influenced by the spin orientation of a chemically bonded nucleus. Spin–spin coupling is easily observed in NMR of hydrogen-1 (1H NMR) since its natural abundance is nearly 100%. Because the nuclear magnetic resonance timescale is rather slow, compared to other spectroscopic methods, changing the temperature of a T2* experiment can also give information about fast reactions, such as the Cope rearrangement or about structural dynamics, such as ring-flipping in cyclohexane.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Suppliers normally quote a percentage of total chromatographic peak area, most often from reversed-phase HPLC. That figure says nothing about what the remaining percentage contains, and it depends on the detection wavelength used. A mass spectrometry result is a separate and stronger check on identity.